Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Leukemia

• Publication date

  2016-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/leu.2015.259PMID 26419509
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.

  2015cited by this paper
• International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

  2014cited by this paper
• The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma

  2014cited by this paper
• Bone marrow plasma macrophage inflammatory protein protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics.

  2014cited by this paper
• State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings.

  2014cited by this paper
• Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.

  2013cited by this paper
• Correlation between Th17 cells and tumor microenvironment.

  2013cited by this paper
• Bone Marrow Monocyte / Macrophage Derived Activin A Mediates the Osteoclastogenic Effect of IL-3 in Multiple Myeloma

  2013cited by this paper
• Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma

  2013cited by this paper
• The Systemic Cytokine Environment Is Permanently Altered in Multiple Myeloma

  2013cited by this paper
• Advances in the Regulation of Osteoclasts and Osteoclast Functions

  2013cited by this paper
• The role of imaging techniques in the management of multiple myeloma

  2012cited by this paper
• Multiple myeloma: a clinical overview.

  2011cited by this paper
• Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.

  2011cited by this paper
• Current and future imaging modalities for multiple myeloma and its precursor states

  2011cited by this paper
• A Novel Role for CCL3 (MIP-1α) in Myeloma-induced Bone Disease via Osteocalcin Downregulation and Inhibition of Osteoblast Function

  2011cited by this paper
• Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1α levels in patients with MGUS.

  2011cited by this paper
• Angiogenesis-Related Cytokines, RANKL, and Osteoprotegerin in Multiple Myeloma Patients in relation to Clinical Features and Response to Treatment

  2011cited by this paper
• A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma.

  2010cited by this paper
• Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

  2010cited by this paper
• Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.

  2010cited by this paper
• The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group

  2010cited by this paper
• The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients.

  2010cited by this paper
• Pathogenesis of myeloma bone disease

  2009cited by this paper
• Serum levels of total-RANKL in multiple myeloma.

  2009cited by this paper
• CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.

  2008cited by this paper
• Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma.

  2008cited by this paper
• The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients.

  2008cited by this paper
• Serum concentrations of DKK‐1 correlate with the extent of bone disease in patients with multiple myeloma

  2008cited by this paper
• Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations.

  2007cited by this paper
• Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment.

  2007cited by this paper
• Myeloma cells and bone marrow osteoblast interactions: Role in the development of osteolytic lesions in multiple myeloma

  2007cited by this paper
• Bortezomib reduces serum dickkopf‐1 and receptor activator of nuclear factor‐κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

  2006cited by this paper
• Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients.

  2006cited by this paper
• IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma.

  2005cited by this paper
• Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.

  2005cited by this paper
• Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma

  2004cited by this paper
• Role of receptor activator of nuclear factor‐kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1‐alpha (MIP‐1a) in monoclonal gammopathy of undetermined significance (MGUS)

  2004cited by this paper
• Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)‐1α and MIP‐1β correlates with lytic bone lesions in patients with multiple myeloma

  2004cited by this paper
• Bone lesions in molecular subtypes of multiple myeloma.

  2004cited by this paper
• Aberrant Chemokine Receptor Expression and Chemokine Production by Langerhans Cells Underlies the Pathogenesis of Langerhans Cell Histiocytosis

  2003cited by this paper
• Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.

  2003cited by this paper
• Macrophage inflammatory protein‐1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM

  2003cited by this paper
• The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

  2003cited by this paper
• Serum levels of macrophage inflammatory protein‐1 alpha (MIP‐1α) correlate with the extent of bone disease and survival in patients with multiple myeloma

  2003cited by this paper
• Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.

  2002cited by this paper
• Serum osteoprotegerin levels in healthy controls and cancer patients.

  2002cited by this paper
• Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment.

  2001cited by this paper
• Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease.

  2001cited by this paper
• Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma.

  2000cited by this paper
• Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.

  2000cited by this paper
• Langerhans cell histiocytosis

  1998cited by this paper
• Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies.

  1996cited by this paper
• And Growth of Myeloma Cells Il-3 Expression by Myeloma Cells Increases Both Osteoclast Formation

  year unknowncited by this paper

• Models of myeloma bone disease: In vivo and in vitro approaches.

  2026cites this paper
• Immune heterogeneity at diagnosis influences treatment response and survival in multiple myeloma.

  2026cites this paper
• Tackling myeloma bone disease: From pathophysiology to cutting-edge therapies.

  2025cites this paper
• Systemic Trafficking of Macrophages in Implant Wear Debris-Induced Periprosthetic Osteolysis.

  2025cites this paper
• Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients

  2024cites this paper
• Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma

  2022cites this paper
• Predictive Immune Markers for Disease Progression in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance

  2022cites this paper
• Pathogenesis and Treatment of Myeloma-Related Bone Disease

  2022cites this paper
• Myeloma-Related Hypercalcemia and Bone Disease

  2022cites this paper
• Biological relationship between bone and myeloma cells

  2022cites this paper
• Translational Potential of RNA Derived From Extracellular Vesicles in Multiple Myeloma

  2021cites this paper
• The Role of Proteasome Inhibitors in Multiple Myeloma Bone Disease and Bone Metastasis: Effects on Osteoblasts and Osteocytes

  2021cites this paper
• A functional three‐dimensional microphysiological human model of myeloma bone disease

  2021cites this paper
• The Pathophysiology of Myeloma Bone Disease: Bone Remodelling and the Role of Osteoclasts

  2021cites this paper
• Receptor binding competition: A paradigm for regulating TGF-β family action.

  2020cites this paper
• Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide

  2020cites this paper
• Multiple Myeloma Associated Bone Disease

  2020cites this paper
• Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment

  2020cites this paper
• Multiple myeloma-A painful disease of the bone marrow.

  2020cites this paper
• CCL28-induced RARβ expression inhibits oral squamous cell carcinoma bone invasion.

  2019cites this paper
• Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients

  2019influential citation
• Delayed enhancement in differential diagnosis of salivary gland neoplasm.

  2019cites this paper
• Does multiparametric US improve diagnostic accuracy in the characterization of small testicular masses?

  2019cites this paper
• Hereditary breast cancer: screening and risk reducing surgery.

  2019cites this paper
• Percutaneous needle biopsy of retroperitoneal lesions: technical developments

  2019cites this paper
• Application of diffusion tensor imaging (DTI) and MR-tractography in the evaluation of peripheral nerve tumours: state of the art and review of the literature

  2019cites this paper
• Diagnostic value/performance of radiological liver imaging during chemoterapy for gastrointestinal malignancy: a critical review

  2019cites this paper
• Radiation-induced brain cavernomas in elderly: review of the literature and a rare case report

  2019cites this paper
• Magnetic resonance enterography (MRE) and ultrasonography (US) in the study of the small bowel in Crohn’s disease: state of the art and review of the literature

  2019cites this paper
• Relationship between diagnostic imaging features and prognostic outcomes in gastrointestinal stromal tumors (GIST)

  2019cites this paper
• Advances in diagnostic and interventional radiology

  2019cites this paper
• Internal hernias: a difficult diagnostic challenge. Review of CT signs and clinical findings

  2019cites this paper
• Ultrasound-guided percutaneous irrigation of calcific tendinopathy: technical developments

  2019cites this paper
• Role of The Osteoclast in Cancer

  2019cites this paper
• Fluid Shear Stress Increases Osteocyte and Inhibits Osteoclasts via Downregulating Receptor-Activator of Nuclear Factor κB (RANK)/Osteoprotegerin Expression in Myeloma Microenvironment

  2019cites this paper
• Why do myeloma patients have bone disease? A historical perspective.

  2019cites this paper
• Bone marrow Dikkopf‐1 levels are a new independent risk factor for progression in patients with smouldering myeloma

  2018cites this paper
• Neurofibromatosis type I and multiple myeloma coexistence: A possible link?

  2018cites this paper
• Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C‐C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia

  2018cites this paper
• Possible targets to treat myeloma-related osteoclastogenesis

  2018cites this paper
• Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI

  2018cites this paper
• Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy

  2018cites this paper
• Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies

  2018cites this paper
• Magnetic Resonance Imaging correlates of benign and malignant alterations of the spinal bone marrow

  2018cites this paper
• Imaging of pediatric foot disorders

  2018cites this paper
• Pathogenesis of bone disease in multiple myeloma: from bench to bedside

  2018cites this paper
• IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts

  2017cites this paper
• L’os du myélome multiple : physiopathologie

  2017cites this paper
• Neoplastic plasma cells generate an inflammatory environment within bone marrow and markedly alter the distribution of T cells between lymphoid compartments

  2017cites this paper
• Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells

  2016cites this paper
• Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.

  2016cites this paper
• IL-32 and multiple myeloma bone disease

  2016cites this paper
• Strong immunoexpression of dickkopf-1 is associated with response to bortezomib in multiple myeloma

  2016cites this paper
• Assessing pain and inflammation in arthritis using novel imaging methods

  2016cites this paper